LINGO1-targeted antibody-drug conjugates improve efficacy and tolerability of antineoplastic therapies in Ewing sarcoma models.
Where this comes from
- Record sourced from PubMed, PMID 42544585.
- Also identified by DOI 10.1172/JCI204641 and PMC identifier 13430015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We reported LINGO1 as a potential marker on Ewing sarcoma cells that could enable targeted drug delivery, improving treatment effectiveness while reducing side effects.
Medical subject headings
- Sarcoma, Ewing
- Bone Neoplasms
- Immunoconjugates
- Membrane Proteins
- Nerve Tissue Proteins
- Neoplasm Proteins
- Antineoplastic Agents